Literature DB >> 1324640

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

E J Goldstein1, D M Citron.   

Abstract

The in vitro activities of seven fluoroquinolones against 290 anaerobes were determined by agar dilution. CI-960 and WIN 57273 inhibited greater than 95% of the strains at less than or equal to 2 micrograms/ml. CI-990 required less than or equal to 16 micrograms/ml. Clustering around 2 to 4 micrograms/ml was noted for Bacteroides fragilis group organisms with CI-990, sparfloxacin, and temafloxacin. Temafloxacin and sparfloxacin inhibited most strains at less than or equal to 2 micrograms/ml. B. fragilis was more susceptible to all quinolones than were the other B. fragilis group strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324640      PMCID: PMC188857          DOI: 10.1128/AAC.36.5.1158

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; L B Rice; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Short prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides species.

Authors:  D M Citron; E J Baron; S M Finegold; E J Goldstein
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

4.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  The in-vitro activity of PD127,391, a new quinolone.

Authors:  A King; C Boothman; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

6.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.

Authors:  M R Visser; M Rozenberg-Arska; H Beumer; I M Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

9.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  28 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Authors:  Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Antianaerobic activity of sulopenem compared to six other agents.

Authors:  Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

4.  In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt; D S Reeves
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.

Authors:  M A Smith; P Alperstein; K France; E M Vellozzi; H D Isenberg
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

7.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.

Authors:  G P Bongaerts; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.